Researchers enhance sarcopenia treatment by analyzing gut bacteria and genetics Personalized strategies are essential for ...

Their recent study suggests that a small molecule drug that targets a specific serotonin receptor could become the first neurotherapeutic treatment for sarcopenia — offering hope for older adults ...

The documented research meticulously dissects the clinical and commercial aspects of various innovative treatments. Sarcopenia therapeutics, which include a mix of small molecules, monoclonal ...

Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which is a serious medical ...

Sarcopenia affects up to 1 in 10 people ages ... the muscles stop contracting because they no longer receive signals from the nerve. Treatments for muscle atrophy vary depending on the degree ...

The loss of muscle mass and strength poses an increasingly significant challenge for an ageing society. Prof. Kristina Norman's team at the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE ...

The licensed technology covers the use of inhibitors of an enzyme termed GCPII (glutamate carboxypeptidase II) for the treatment of sarcopenia. The levels of GCPII increase with aging and its ...

Aimed at providing stakeholders with a robust understanding of the treatments under investigation, the report sheds light on emerging therapies poised to revolutionize the management of Sarcopenia—an ...